<< Back to News

New FDA Approval for Genentech's ALECENSA®

On November 6, 2017, ALECENSA® (alectinib) was approved by the FDA for the first-line treatment of patients with anaplastic lymphoma kinase (ALK)–positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. 

The FDA approval letter for ALECENSA can be found at https://www.genentech-access.com/ALECENSA

The full Prescribing Information for ALECENSA can be found at https://www.gene.com/download/pdf/alecensa_prescribing.pdf